A series of 21 anilinobenzimidazoles with a 2,4-difl uorophenyl group were synthesized and their minimum inhibitory concentrations (MIC) determined by the tube dilution method. Most of the compounds exhibited excellent MIC values against Staphylococcus aureus and methicillin-resistant S. aureus (MRSA). Among them, compound 27 having dibromo substitution at the 4-and 6-position of the benzimidazole ring showed the best antifungal activity against Candida krusei with a MIC value of 3.12 µg/mL that surpassed that of the reference drug fl uconazole.
Introduction
Previously, we have reported the synthesis and very potent antistaphylococcal activities of a series of 2-anilinobenzimidazole derivatives (Özden et al., 2008) . Compounds I and II ( Fig. 1) were identifi ed as the most active agents against Staphylococcus aureus and methicillin-resistant S. aureus (MRSA), with MIC values of 0.095 and 0.19 µg/mL, respectively. According to our preliminary results, these compounds exhibited good in vitro antifungal activity as well, particularly against Candida krusei.
C. krusei is a well known fungal pathogen in patients with hematologic malignancies as well as in transplant recipients. It is naturally resistant against some of the antifungal azoles such as fl uconazole. The mortality rate due to C. krusei fungemia is much higher than that due to more common C. albicans infections. Therefore it is urgently needed to discover new agents that will be effective against C. krusei.
The use of classical antifungal therapies has been limited due to toxicity, low effi cacy, and resis tance. New formulations and structural modifi cations have been developed which increase the absorption and effi cacy. These new agents may provide additional options for the treatment of superfi cial fungal infections, and they may help to overcome the limitations of current treatments (Gupta and Tomas, 2003) . Among them, three new triazole drugs, viz. voriconazole, ravuconazole, and posaconazole ( Fig. 2) , with broadspectrum activity, have been developed and may be of use in both systemic and superfi cial fungal infections. Voriconazole has a high bioavailability and has been successfully used with immunocompromised patients, including those infected with C. krusei. Ravuconazole is active against Candida spp., Cryptococcus neoformans, Aspergillus fumigates and dermatophytes. Posaconazole shows excellent activity against Candida spp., including C. krusei, C. glabrata, C. guilliermondii, and C. dubliniensis, all of which are inherently less susceptible to fl uconazole. All of these triazole derivatives have a 2,4-difl uorophenyl ring, which is a very effective pharmacophore group for good anti fungal activity. In studies aimed at the develop ment of fl uconazole derivatives, it has been reported that compounds with a 2,4-difl uorophenyl group showed the best in vivo antifungal activity (Jiang et al., 2011; Kagoshima and Konosu, 2006) . In the present study, we have designed a series of novel anilinobenzimidazoles, containing a difl uorophenyl group, with the aim to fi nd an antifungal spectrum against Candida species.
Results and Discussion

Chemical syntheses
Syntheses of non-commercial starting materials were carried out according to methods described in the literature (Scheme 1). 4,5-Dibromo-o-phenylenediamine (2) was prepared via the acylation of o-phenylenediamine with p-tolylsulfonyl chloride, followed by addition of bromine at 0 -5 °C. Finally, hydrolyzation of 1 with concentrated H 2 SO 4 afforded the desired compound 2 ( Cheeseman, 1962) . 3,6-Dichloro-o-phenylenediamine (3) was prepared by nitration of 1,4-dichlorobenzene followed by reduction with Sn/SnCl 2 (Baudy et al., 1993) . Reduction of 2,4-dibromo-6-nitroaniline by Zn/acetic acid gave 3,5-dibromo-o-phenylenediamine (4) under moderate conditions (Scott and Tomlinson, 1959) .
Similarly, 3,4,5-trifl uoro-o-phenylenediamine (5) was prepared from its nitro derivative (Keana et al., 1995) . Heating of 2-nitroaniline with iodine monochloride in anhydrous sodium acetate/glacial acetic acid gave compound 6 (Price et al., 2003) , which was reduced to 4-iodo-o-phenylenediamine (7) (Wilson and Hunt, 1983) . 5-Imidazol-1-yl-2-nitroaniline (8) was prepared by the reaction of 5-chloro-2-nitroaniline with imidazole in DMSO/KOH. Reduction of this compound with H 2 /Pd-C afforded 4-imidazol-1-yl-o-phenylenediamine (9) (Güngör et al., 1992) . Using similar catalytic hydrogenation conditions, 4-amino-3-nitrobenzonitrile was converted to 3,4-diaminobenzonitrile (10) (Fairley et al., 1993) .
The target anilinobenzimidazoles were synthesized using the three different methods given in Scheme 2:
Method A: Synthesis of 2-N-(substituted) amino benzimidazoles utilizing CuCl-promoted intramolecular cyclization of N-(2-aminoaryl) thioureas (Wang et al., 2004) .
Method B: Cyclization using an ethyl carbodiimide polymer (EDC) polymer (Cee and Downing, 2006) .
Method C: Heating of 1-(4-fl uorobenzyl)-2-chloro ben zimidazole with 2,4-difl uoroaniline at high temperature (Tunçbilek et al., 1997) . 
Ravuconazole
Antimicrobial activities
The in vitro antifungal and antistaphylococcal activities of the synthesized compounds were evaluated against two pathogenic fungi, viz. C. albicans ATCC 10231 and C. krusei ATCC 6258, and against two bacteria, viz. S. aureus ATCC 25923 and methicillin-resistant S. aureus ATCC 43300 (MRSA). Sultamicillin, ampicillin, fl uconazole, and miconazole were used as reference compounds. The in vitro minimal inhibitory concentrations (MIC 100 ) of the compounds were determined using the microbroth dilution method (Jorgensen et al., 1999; Shadomy and Pfaller, 1991 Table I . As mentioned earlier, these compounds were prepared for their promising antifungal activities. However, they exhibited better antistaphylococcal rather than antifungal activities. Among compounds 11 -31, compound 27 with bromine atoms at the 4-and 6-position of the benzimidazole ring showed the best antifungal activity against C. krusei with a MIC value of 3.12 µg/mL, surpassing that of fl uconazole. It is well known that fl uconazole has no inhibitory effect against C. krusei at 25 µg/mL. Additionally, none of the synthesized compounds had signifi cant inhibitory activity against C. albicans. Thus, in contrast to our expectations, substitution of the benzimidazoles with 2,4-difl uoroaniline at C-2 is not benefi cial for the antifungal activity.
Most of the compounds were active against both S. aureus and MRSA. The activities of 22 and 29 were equal to that of ampicillin against S. aureus (0.39 µg/mL). Compounds 19, 24 -28 had very potent activity against both S. aureus and MRSA, with MIC values of 0.78 -1.56 µg/mL. Halogen and CF 3 substitution of the benzimidazole ring increased the antibacterial activity. Addi tionally, while ampicillin and sultamicillin were practically inactive against MRSA (25 µg/ mL), the anilinobenzimidazoles which were effective against S. aureus were also active against MRSA. This is a signifi cant advantage over the clinically used drugs, since vancomycin is the only antibiotic that is effective against MRSA infections. Antibacterial activity completely disappeared with the substitution of the N 1 -imidazole ring with the p-fl uorobenzyl group, as exemplifi ed for 31. This fi nding suggests that the tautomeric NH group of the imidazole ring could be important for a potent antistaphylococcal effect.
Experimental
General
Melting points were measured with a capillary melting point apparatus (Büchi Labortechnik, Flawil, Switzerland) and were uncorrected. ethanol and dry HCl gas was passed through the solution. The salts frequently contained fractional moles of solvation water and/or ethanol; for compounds 14, 16, 17, 19, and 22, 1 H NMR spectroscopy confi rmed the presence of solvent.
Method A
A mixture of the corresponding o-phenylenediamine (4 mmol) and substituted phenylisothiocyanate (4 mmol) was heated under refl ux in acetonitrile (2.7 mL) and toluene (1 mL) for 15 min. To this mixture cellite (0.4 g), N-ethyldiisopropylamine (2 mL), and CuCl (0.9 g) were added. The resulting mixture was heated to 80 °C and kept at this temperature for 1 h. The reaction mixture was then cooled to 40 °C and fi ltered at this temperature. The fi ltrate was extracted with 7% ammonium hydroxide and dried over anhydrous Na 2 SO 4 ; then the solvent was evaporated. The residue was purifi ed by column chromatography on silica gel with a mixture of ethyl acetate/nhexane in the appropriate ratio.
Method B
A mixture of the corresponding o-phenylenediamine (4 mmol), substituted phenylisothiocyanate (4 mmol) and 1.590 g of 1-(3-dimetylaminopropyl)-3-ethyl carbodiimide polymer (EDC) in THF (15 mL) was heated in a sealed tube at 70 °C, for 3 h. The reaction mixture was then cooled, fi ltered, and the solvent evaporated.
Method C
A mixture of 1-(p-fl ourobenzyl)-2-chloro-1H-benzimidazole (1 mmol) and 2,4-difl uoroaniline (1 mmol) in DMF (0.8 mL) was heated under refl ux for 18 h at 140 °C. The reaction mixture was cooled, then sodium hydroxide solution (20%) was added, and extracted with ethyl acetate. C 59.32, H 3.06, N 15.96; found C 59.37, H 3.05, N 15.50 . (Özden et al., 2008) , Method A: The crude product was purifi ed by chromatography on silica gel (EtOAc/n-hexane 1:3 H 2.78, N 11.36; found C 43.03, H 3.05, m, m, 5'), 7.68 (1H, d, J o = 8.4 Hz, m, 6' H 3.22, N 16.76; found C 51.71, H 3.23, N 16.31 .
2-(2,4-Difl uoroanilino)-1H-benzimidazole hydrochloride (11), Method
5(6)-Fluoro-2-(2,4-difluoroanilino)-1H-benzimidazole (12), Method
5(6)-Chloro-2-(2,4-difluoroanilino)-1H-benzimidazole (13)
5(6)-Trifluoromethyl-2-(2,4-difluo roanilino)-1H-benzimidazole hydrochloride (19), Method A:
The crude product was purifi ed by chromatography on silica gel (EtOAc/n-hexane 1:3). − Yield 17.2%. − M.p. 211 -215 °C. − 1 H NMR (DMSOd 6 ): δ = 7. 22 -7.27 (1H, m, H-3'), 7.49 -7.55 (1H, m, H-5'), 7.58 (2H, s, H-4, 6), 7.69 (1H, s, H-7), 7.73 -7.79 (1H, m, H-6') C 48.33, H 3.24, N 11.27; found C 47.96, H 3.16, C 56.87, H 3.97, N 13.26; found C 57.08, H 3.38, N 12.67 . ( C 60.85, H 3.67, N 22.18; found C 61.34, H 3.97, N 21.59. 5, O: calcd. C 34.81, H 2.02, N 9.37; found C 34.69, H 1.89, N 9.50. 4, , Method B: The crude product was purifi ed by chromatography on silica gel (EtOAc/n-hexane 1:3). − Yield 13.5%. − M.p. 192 -196 °C. − 1 H NMR (CD 3 OD): δ = 7.17 -7.21 (1H, m, H-3'), 7.28 -7.33 (1H, m, H-5'), 7.50 (1H,
2-(2,4-Difluoroanilino)-5(6)-(imida zol-1-yl)-1H-benzimidazole
